ALNY
Alnylam Pharmaceuticals Inc
NASDAQ: ALNY · HEALTHCARE · BIOTECHNOLOGY
$301.19
-0.30% today
Updated 2026-04-29
Market cap
$40.19B
P/E ratio
129.82
P/S ratio
10.82x
EPS (TTM)
$2.32
Dividend yield
—
52W range
$246 – $496
Volume
1.1M
WallStSmart proprietary scores
59
out of 100
Grade: C+
Hold
Investment rating
8.0
Growth
A5.0
Quality
C+7.0
Profitability
B+6.7
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$449.12
+49.12%
12-Month target
$15.91
-94.72%
Intrinsic (DCF)
$2,113.13
Margin of safety
+84.75%
6 Strong Buy14 Buy8 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ ROE 73.30% — strong efficiency
+ Free cash flow $140.26M — positive
+ Revenue growth 84.90% QoQ
+ 84.75% below intrinsic value
Risks
- P/E 129.82x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $1.04B | $1.83B | $2.25B | $3.71B | $3.71B | $4.5B |
| Net income | $-1.13B | $-440.24M | $-278.16M | $313.75M | $186.42M | — |
| EPS | — | — | — | — | $2.32 | $7.46 |
| Free cash flow | $-613.33M | $41.95M | $-42.59M | $465.38M | $140.26M | — |
| Profit margin | -109.04% | -24.08% | -12.37% | 8.45% | 8.45% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-06 | MCLAUGHLIN, MELISSA | Sale | 909 | $329.76 |
| 2026-04-06 | MCLAUGHLIN, MELISSA | Sale | 829 | $330.46 |
| 2026-04-06 | MCLAUGHLIN, MELISSA | Sale | 293 | $331.89 |
Peer comparison
Smart narrative
Alnylam Pharmaceuticals Inc trades at $301.19. representing a P/E of 129.82x trailing earnings. Our Smart Value Score of 59/100 indicates the stock is fair. TTM revenue stands at $3.71B. with profit margins at 8.45%. Our DCF model estimates intrinsic value at $2,113.13.
Frequently asked questions
What is Alnylam Pharmaceuticals Inc's stock price?
Alnylam Pharmaceuticals Inc (ALNY) trades at $301.19.
Is Alnylam Pharmaceuticals Inc overvalued?
Smart Value Score 59/100 (Grade C+, Hold). DCF value $2,113.13.
What is the price target of Alnylam Pharmaceuticals Inc (ALNY)?
The analyst target price is $449.12, representing +49.1% upside from the current price of $301.19.
What is the intrinsic value of Alnylam Pharmaceuticals Inc (ALNY)?
Based on our DCF model, intrinsic value is $2,113.13, a +84.8% margin of safety versus $301.19.
What is the future stock price of ALNY by 2030?
Our research-backed model estimates Alnylam Pharmaceuticals Inc could reach $1,084.09 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Alnylam Pharmaceuticals Inc's revenue?
TTM revenue is $3.71B.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.82x
ROE73.30%
Beta0.38
50D MA$320.98
200D MA$393.04
Shares out0.13B
Float0.13B
Short ratio—
Avg volume1.1M
Performance
1 week-1.42%
1 month-8.38%
3 months-10.91%
YTD-24.26%
1 year—
3 years—
5 years—